Eli Lilly’s Foundayo Momentum Overpowers a $200 Million Rebate Headache
27.05.2026 - 14:23:58 | boerse-global.de
Eli Lilly has spent the past month cementing its position at the front of the GLP-1 gold rush, with its newly approved oral therapy Foundayo delivering strong efficacy in elderly patients and a fresh round of prescriptions backing up the bullish analyst forecasts. Yet behind the headline gains, the company is fighting a separate battle over the financial plumbing of its older diabetes drug Trulicity, where allegations of fraudulent rebate claims have escalated into a full-blown federal lawsuit.
Data From the Real Edge of the Market
On the European Congress on Obesity stage in May 2026, Eli Lilly presented post-hoc analyses of the phase 3 trials ATTAIN-1 and ATTAIN-2. The key finding: patients aged 65 and older lost an average of 13% of their body weight on Foundayo, regardless of whether they also had type 2 diabetes. The safety profile held up as well as in younger participants, a point the company stressed because seniors represent one of the fastest-growing cohorts in metabolic disease.
Foundayo won U.S. approval in April, and by the end of its third week on the market it had already captured around 5,600 prescriptions. Analysts project the drug — whose active ingredient is orforglipron — could reach annual sales of nearly $14.4 billion by 2031. The entire oral GLP-1 segment is expected to top $34 billion by then, placing Eli Lilly in a direct race against Novo Nordisk’s oral semaglutide.
The Legal Detour That Won’t Derail the Story
While the pipeline narrative looks bright, Eli Lilly is simultaneously navigating a messy rebate dispute that involves more than $200 million. The company filed suit in the Southern District of Florida, alleging that a network of intermediaries — including DrugPlace entities in Florida and Tennessee, Community Health Initiative, multiple wholesalers, Galaxy Pharmacy, and several named individuals — used a patient cost-sharing program tied to members of the Church of God in Christ as a cover to submit illegitimate rebate claims on Trulicity prescriptions.
Should investors sell immediately? Or is it worth buying Eli Lilly?
The scheme, as described by Eli Lilly, involved buying large quantities of Trulicity, filing manufacturer rebate requests through brokers, and then reselling the product on the secondary market to large wholesalers. The company claims the rebates were paid out between 2020 and 2024 and that the total improperly disbursed sum exceeds $200 million. It is seeking an injunction against further claims, repayment of the disputed amounts, disgorgement of alleged profits, and damages.
The Church of God in Christ, named in connection with the program, has denied knowledge of the actions and said it neither supported nor approved them. It is not listed as a defendant.
A Controlled Risk Next to a Surging Top Line
Relative to the company’s financial weight, the $200 million figure is modest. Eli Lilly reported first-quarter revenue of $19.8 billion, up 56% year-on-year, and raised its full-year guidance to between $82 billion and $85 billion. The suit represents just over 1% of a single quarter’s sales.
Still, the case has operational implications. It touches the opaque world of pharmaceutical rebate management, where list prices are only the visible tip and the true net revenue depends on a maze of pharmacy benefit managers, wholesalers, and claims processors. Eli Lilly argues that the rebate requests were routed through intermediaries to conceal their origin, raising the question of how well the company can police its own distribution channels without disrupting the wider rebate system.
Where the Real Growth Lives
Trulicity itself has been fading from the center of the growth story. U.S. sales fell to $2.9 billion in 2025, down from $3.369 billion the year before and a peak of $5.4 billion in earlier years. The heavy lifting now comes from the next-generation portfolio: Mounjaro generated $8.7 billion in the first quarter alone, a 125% jump, and Zepbound added $4.16 billion.
Eli Lilly at a turning point? This analysis reveals what investors need to know now.
Those numbers explain why the stock market has largely shrugged off the legal noise. Eli Lilly shares closed Tuesday at €917.30, still up nearly 24% over the past 30 days and around 43% higher over 12 months. The 30?day climb is slightly above what was reported in some earlier dispatches, but the trend is consistent: the market is betting on Foundayo, Mounjaro, and the pipeline beyond.
The company is also working on next?generation injectable candidates targeting long?term complications like heart disease and hypertension. Those studies, if successful, would expand the addressable market even further. The next clinical milestones from that program will show whether Eli Lilly can widen its lead in the GLP?1 class — and keep the legal distraction firmly in the rearview mirror.
Ad
Eli Lilly Stock: New Analysis - 27 May
Fresh Eli Lilly information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
